Scopolamine and amphetamine produce similar decision-making deficits on a rat gambling task via independent pathways

Behavioural Brain Research

Volumn 281, Issue , 2015, Pages 86-95

  Silveira, Mason M ^a   Malcolm, Emma ^b   Shoaib, Mohammed ^b   Winstanley, Catharine A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acetylcholine; Impulsivity; Muscarinic; Nicotinic; Risky decision making; Schizophrenia

Indexed keywords

DEXAMPHETAMINE; MECAMYLAMINE; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; OXOTREMORINE M; SCOPOLAMINE BROMIDE; AMPHETAMINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; OXOTREMORINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; COHORT ANALYSIS; CONNECTOME; DECISION MAKING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; GAMBLING; IMPULSIVENESS; MALE; MENTAL PERFORMANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PUNISHMENT; RAT; REWARD; TRAINING; ANIMAL; DRUG EFFECTS; LONG EVANS RAT; PSYCHOLOGY;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CHOICE BEHAVIOR; DECISION MAKING; GAMBLING; MALE; MECAMYLAMINE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; OXOTREMORINE; RATS; RATS, LONG-EVANS; REWARD; SCOPOLAMINE HYDROBROMIDE;

EID: 84921304954     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.12.029     Document Type: Article

References (74)

1. Lee D. Decision making: from neuroscience to psychiatry. Neuron 2013, 78(2):233-248. 10.1016/j.neuron.2013.04.008.
2. Bechara A., Damasio A.R., Damasio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50(1-3):7-15.
3. Garon N., Moore C., Waschbusch D.A. Decision making in children with ADHD only, ADHD-anxious/depressed, and control children using a child version of the Iowa gambling task. J Atten Disord 2006, 9(4):607-619. 10.1177/1087054705284501.
4. Goudriaan A.E., Oosterlaan J., de Beurs E., van den Brink W. Psychophysiological determinants and concomitants of deficient decision making in pathological gamblers. Drug Alcohol Depend 2006, 84(3):231-239. 10.1016/j.drugalcdep.2006.02.007.
5. Sevy S., Burdick K.E., Visweswaraiah H., Abdelmessih S., Lukin M., Yechiam E., et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007, 92(1-3):74-84. 10.1016/j.schres.2007.01.005.
6. Sinz H., Zamarian L., Benke T., Wenning G.K., Delazer M. Impact of ambiguity and risk on decision making in mild Alzheimer's disease. Neuropsychologia 2008, 46(7):2043-2055. 10.1016/j.neuropsychologia.2008.02.002.
7. Zeeb F.D., Robbins T.W., Winstanley C.A. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. Neuropsychopharmacology 2009, 34(10):2329-2343. 10.1038/npp.2009.62.
8. Zeeb F.D., Winstanley C.A. Lesions of the basolateral amygdala and orbitofrontal cortex differentially affect acquisition and performance of a rodent gambling task. J Neurosci 2011, 31(6):2197-2204. 10.1523/JNEUROSCI.5597-10.2011.
9. Zeeb F.D., Winstanley C.A. Functional disconnection of the orbitofrontal cortex and basolateral amygdala impairs acquisition of a rat gambling task and disrupts animals' ability to alter decision-making behavior after reinforcer devaluation. J Neurosci 2013, 33(15):6434-6443. 10.1523/JNEUROSCI.3971-12.2013.
10. Zeeb F.D., Wong A.C., Winstanley C.A. Differential effects of environmental enrichment, social-housing, and isolation-rearing on a rat gambling task: dissociations between impulsive action and risky decision-making. Psychopharmacology (Berl) 2013, 225(2):381-395. 10.1007/s00213-012-2822x.
11. Baarendse P.J., Winstanley C.A., Vanderschuren L.J. Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. Psychopharmacology (Berl) 2013, 225(3):719-731. 10.1007/s00213-012-2857-z.
12. Young J.W., van Enkhuizen J., Winstanley C.A., Geyer M.A. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol 2011, 25(7):934-943. 10.1177/0269881111400646.
13. Jones C.A., Watson D.J., Fone K.C. Animal models of schizophrenia. Br J Pharmacol 2011, 164(4):1162-1194. 10.1111/j.1476-5381.2011.01386.x.
14. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu Rev Psychol 1989, 40:191-225. 10.1146/annurev.ps.40.020189.001203.
15. Jones C.K., Eberle E.L., Shaw D.B., McKinzie D.L., Shannon H.E. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 2005, 312(3):1055-1063. 10.1124/jpet.104.075887.
16. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 2001, 299(2):782-792.
17. Andersen M.B., Fink-Jensen A., Peacock L., Gerlach J., Bymaster F., Lundbaek J.A., et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 2003, 28(6):1168-1175. 10.1038/sj.npp.1300151.
18. Maehara S., Hikichi H., Satow A., Okuda S., Ohta H. Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacol Biochem Behav 2008, 91(1):140-149. 10.1016/j.pbb.2008.06.023.
19. 4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol 2011, 14(9):1233-1246. 10.1017/S1461145710001549.
20. Forster G.L., Blaha C.D. Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 2000, 12(10):3596-3604.
21. Forster G.L., Blaha C.D. Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur J Neurosci 2003, 17(4):751-762.
22. Laplante F., Zhang Z.W., Huppé-Gourgues F., Dufresne M.M., Vaucher E., Sullivan R.M. Cholinergic depletion in nucleus accumbens impairs mesocortical dopamine activation and cognitive function in rats. Neuropharmacology 2012, 63(6):1075-1084. 10.1016/j.neuropharm.2012.07.033.
23. Threlfell S., Clements M.A., Khodai T., Pienaar I.S., Exley R., Wess J., et al. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci 2010, 30(9):3398-3408. 10.1523/JNEUROSCI.5620-09.2010.
24. Threlfell S., Lalic T., Platt N.J., Jennings K.A., Deisseroth K., Cragg S.J. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75(1):58-64. 10.1016/j.neuron.2012.04.038.
25. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995, 12(1):3-16. 10.1016/0893-133X(94)00054-4.
26. Floresco S.B., St Onge J.R., Ghods-Sharifi S., Winstanley C.A. Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making. Cogn Affect Behav Neurosci 2008, 8(4):375-389. 10.3758/CABN.8.4.375.
27. Yu A.J., Dayan P. Uncertainty, neuromodulation, and attention. Neuron 2005, 46(4):681-692. 10.1016/j.neuron.2005.04.026.
28. Jones C.K., Shannon H.E. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 2000, 294(3):1017-1023.
29. Mirza N.R., Stolerman I.P. The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology (Berl) 2000, 148(3):243-250.
30. Cardinal R.N., Aitken M. ANOVA for the behavioural sciences researcher 2006, London, Lawrence Erlbaum Associates.
31. McDonald J. Handbook of biological statistics 2009, Sparky House Publishing, Baltimore. 2nd ed.
32. Barrus M.M., Hosking J.G., Zeeb F.D., Tremblay M., Winstanley C.A. Disadvantageous decision-making on a rodent gambling task is associated with increased motor impulsivity in a population of male rats. J Psychiatry Neurosci 2014, 39(5):140045.
33. Yilmazer-Hanke D.M. Morphological correlates of emotional and cognitive behaviour: insights from studies on inbred and outbred rodent strains and their crosses. Behav Pharmacol 2008, 19(5-6):403-434. 10.1097/FBP.0b013e32830dc0de.
34. Karczmar A.G. SpringerLink eBooks - biomedical and life sciences (2007) & Ebrary eBooks (2007). Exploring the vertebrate cholinergic nervous system 2007, Retrieved from. http://gw2jh3xr2c.search.serialssolutions.com/?sid=sersol%26SS_jc=TC0000152396%26title=Exploringthevertebratecholinergicnervoussystem.
35. Moore H., Dudchenko P., Bruno J.P., Sarter M. Toward modeling age-related changes of attentional abilities in rats: simple and choice reaction time tasks and vigilance. Neurobiol Aging 1992, 13(6):759-772.
36. Ruotsalainen S., Miettinen R., MacDonald E., Koivisto E., Sirviö J. Blockade of muscarinic, rather than nicotinic, receptors impairs attention, but does not interact with serotonin depletion. Psychopharmacology (Berl) 2000, 148(2):111-123.
37. Pratt W.E., Kelley A.E. Nucleus accumbens acetylcholine regulates appetitive learning and motivation for food via activation of muscarinic receptors. Behav Neurosci 2004, 118(4):730-739. 10.1037/0735-7044.118.4.730.
38. Mendez I.A., Gilbert R.J., Bizon J.L., Setlow B. Effects of acute administration of nicotinic and muscarinic cholinergic agonists and antagonists on performance in different cost-benefit decision making tasks in rats. Psychopharmacology (Berl) 2012, 224(4):489-499. 10.1007/s00213-012-2777-y.
39. Ostlund S.B., Kosheleff A.R., Maidment N.T. Differential effects of systemic cholinergic receptor blockade on pavlovian incentive motivation and goal-directed action selection. Neuropsychopharmacology 2014, 39(6):1490-1497. 10.1038/npp.2013.348.
40. Picciotto M.R., Higley M.J., Mineur Y.S. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 2012, 76(1):116-129. 10.1016/j.neuron.2012.08.036.
41. Chudasama Y., Robbins T.W. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl) 2004, 174(1):86-98. 10.1007/s00213-004-1805-y.
42. Croxson P.L., Kyriazis D.A., Baxter M.G. Cholinergic modulation of a specific memory function of prefrontal cortex. Nat Neurosci 2011, 14(12):1510-1512. 10.1038/nn.2971.
43. McGaughy J., Dalley J.W., Morrison C.H., Everitt B.J., Robbins T.W. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. J Neurosci 2002, 22(5):1905-1913.
44. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002, 163(3-4):362-380. 10.1007/s00213-002-1154-7.
45. Robbins T.W., Granon S., Muir J.L., Durantou F., Harrison A., Everitt B.J. Neural systems underlying arousal and attention. Implications for drug abuse. Ann NY Acad Sci 1998, 846:222-237.
46. Anderson K.G., Diller J.W. Effects of acute and repeated nicotine administration on delay discounting in Lewis and Fischer 344 rats. Behav Pharmacol 2010, 21(8):754-764. 10.1097/FBP.0b013e328340a050.
47. Dallery J., Locey M.L. Effects of acute and chronic nicotine on impulsive choice in rats. Behav Pharmacol 2005, 16(1):15-23.
48. Kolokotroni K.Z., Rodgers R.J., Harrison A.A. Acute nicotine increases both impulsive choice and behavioural disinhibition in rats. Psychopharmacology (Berl) 2011, 217(4):455-473. 10.1007/s00213-011-2296-2.
49. Mendez I.A., Damborsky J.C., Winzer-Serhan U.H., Bizon J.L., Setlow B. A4β2 and α7 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks. Neuroscience 2013, 230:121-131. 10.1016/j.neuroscience.2012.10.067.
50. Picciotto M.R., Caldarone B.J., King S.L., Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 2000, 22(5):451-465. 10.1016/S0893-133X(99)00146-3.
51. Charpantier E., Barnéoud P., Moser P., Besnard F., Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 1998, 9(13):3097-3101.
52. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003, 6(9):968-973. 10.1038/nn1103.
53. Weiner D.M., Levey A.I., Brann M.R. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A 1990, 87(18):7050-7054.
54. Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96(18):10483-10488.
55. Grilli M., Patti L., Robino F., Zappettini S., Raiteri M., Marchi M. Release-enhancing pre-synaptic muscarinic and nicotinic receptors co-exist and interact on dopaminergic nerve endings of rat nucleus accumbens. J Neurochem 2008, 105(6):2205-2213. 10.1111/j.1471-4159.2008.05307.x.
56. Gronier B., Perry K.W., Rasmussen K. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology (Berl) 2000, 147(4):347-355.
57. Ichikawa J., Chung Y.C., Li Z., Dai J., Meltzer H.Y. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002, 958(1):176-184.
58. Jeon J., Dencker D., Wörtwein G., Woldbye D.P., Cui Y., Davis A.A., et al. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci 2010, 30(6):2396-2405. 10.1523/JNEUROSCI.3843-09.2010.
59. Heidbreder C., Feldon J. Amphetamine-induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens. Synapse 1998, 29(4):310-322. 10.1002/(SICI)1098-2396(199808)29:4<310::AID-SYN3>3.0.CO;2-8.
60. Mattsson A., Olson L., Svensson T.H., Schilström B. Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum. Exp Neurol 2007, 208(1):73-79. 10.1016/j.expneurol.2007.07.012.
61. Swerdlow N.R., Mansbach R.S., Geyer M.A., Pulvirenti L., Koob G.F., Braff D.L. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl) 1990, 100(3):413-416.
62. Hutson P.H., Tarazi F.I., Madhoo M., Slawecki C., Patkar A.A. Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders. Pharmacol Ther 2014, 10.1016/j.pharmthera.2014.03.005.
63. De Vries T.J., Homberg J.R., Binnekade R., Raasø H., Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 2003, 168(1-2):164-169. 10.1007/s00213-003-1422-1.
64. Tzavara E.T., Degroot A., Wade M.R., Davis R.J., Nomikos G.G. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. Eur Neuropsychopharmacol 2009, 19(3):196-204. 10.1016/j.euroneuro.2008.11.003.
65. Wiskerke J., Stoop N., Schetters D., Schoffelmeer A.N., Pattij T. Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice. PLoS ONE 2011, 6(10):e25856. 10.1371/journal.pone.0025856.
66. Cole B.J., Robbins T.W. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septic on performance of a 5-choice serial reaction time task in rats: implications for theories of selective attention and arousal. Behav Brain Res 1989, 33(2):165-179.
67. Economidou D., Theobald D.E., Robbins T.W., Everitt B.J., Dalley J.W. Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens. Neuropsychopharmacology 2012, 37(9):2057-2066. 10.1038/npp.2012.53.
68. Pattij T., Janssen M.C., Vanderschuren L.J., Schoffelmeer A.N., van Gaalen M.M. Involvement of dopamine D1 and D2 receptors in the nucleus accumbens core and shell in inhibitory response control. Psychopharmacology (Berl) 2007, 191(3):587-598. 10.1007/s00213-006-0533-x.
69. Pezze M.A., Dalley J.W., Robbins T.W. Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 2007, 32(2):273-283. 10.1038/sj.npp.1301073.
70. Jones D.N., Higgins G.A. Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl) 1995, 120(2):142-149.
71. Rhodes M.E., Billings T.E., Czambel R.K., Rubin R.T. Pituitary-adrenal responses to cholinergic stimulation and acute mild stress are differentially elevated in male and female M(2) muscarinic receptor knockout mice. J Neuroendocrinol 2005, 17(12):817-826. 10.1111/j.1365-2826.2005.01376.x.
72. Rhodes M.E., Rubin R.T., McKlveen J.M., Karwoski T.E., Fulton B.A., Czambel R.K. Pituitary-adrenal responses to oxotremorine and acute stress in male and female M1 muscarinic receptor knockout mice: comparisons to M2 muscarinic receptor knockout mice. J Neuroendocrinol 2008, 20(5):617-625. 10.1111/j.1365-2826.2008.01700.x.
73. Sun H., Green T.A., Theobald D.E., Birnbaum S.G., Graham D.L., Zeeb F.D., et al. Yohimbine increases impulsivity through activation of camp response element binding in the orbitofrontal cortex. Biol Psychiatry 2010, 67(7):649-656. 10.1016/j.biopsych.2009.11.030.
74. Fobbs W.C., Mizumori S.J. Cost-benefit decision circuitry: proposed modulatory role for acetylcholine. Prog Mol Biol Transl Sci 2014, 122:233-261. 10.1016/B978-0-12-420170-5.00009-X.